![[Lung Cancer Precision Medicine] New Oral Targeted Option: Mobocertinib Receives FDA Breakthrough Approval for EGFR E...](/_next/image?url=%2Fimages%2Fblog%2Flungcanceregfrexon20usemobocertinib-0.webp&w=3840&q=75)
[Lung Cancer Precision Medicine] New Oral Targeted Option: Mobocertinib Receives FDA Breakthrough Approval for EGFR Exon 20 Insertion Mutations
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Mobocertinib: A New Targeted Treatment for EGFR Exon 20 Insertion Mutations
For patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, treatment is shifting from conventional chemotherapy toward more precise targeted therapy. The US FDA granted accelerated approval to the oral drug Mobocertinib for patients whose disease has progressed following platinum-based chemotherapy, offering a more convenient treatment option for this specific mutation group.
1. Clinical Trial 101: Interpreting Efficacy Data
The approval is primarily based on data from the international multicenter Clinical Trial 101 (NCT02716116).
Key Performance Metrics:
- Objective Response Rate (ORR): 28%
- Median Duration of Response (DoR): 17.5 months
- Convenience: Once-daily oral 160 mg dosing significantly improves patient quality of life compared to drugs requiring inpatient infusion
2. Safety Profile and Side Effect Alerts
While Mobocertinib offers convenience, side effect management is equally critical. Japanese specialist medical teams pay particular attention to:
- Common gastrointestinal reactions: Diarrhea (≥20%), nausea, vomiting
- Skin and mucosal reactions: Rash, paronychia, stomatitis
- Cardiac toxicity monitoring: Close attention to QTc interval prolongation; regular ECG monitoring is recommended
3. Companion Diagnostics: The Key to Precision Medicine
Alongside Mobocertinib, the Oncomine Dx Target Test — an advanced genetic testing tool — was also approved. Leading Japanese hospitals typically use such precision tests to accurately identify patients eligible for this treatment, ensuring therapeutic efficacy.
Medical Supporter Connects You to Japan's Advanced Medical Care
Facing a rare mutation, access to accurate information and appropriate treatment pathways is critical. The Medical Supporter team can assist with medical record translation and facilitate communication with Japan's leading lung cancer specialists to assess the feasibility of Mobocertinib or other latest targeted therapies in your treatment plan.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4